Trainee Solicitor

Laura Mole

01923 690091
laura.mole@mablaw.com

Laura Mole is a trainee solicitor at Matthew Arnold & Baldwin LLP. Laura completed her law degree at Brunel University in 2007 having been awarded a First Class grading for her final year dissertation project on European Patent Law and Biotech patents. Laura went on to successfully complete the Legal Practice Course at the College of Law graduating with a top grade Distinction. Laura is currently undergoing her third training contract seat in the Property Litigation Department and pursuing her passion for intellectual property as a member of the Pharmaceutical and Life Sciences Sector Group Team.

Latest news and views from Laura Mole

RSS

European Patent Office apply Enlarged Board of Appeal Ruling on the Surgical Method Exclusion from Patentability

23 February 2012 | Laura Mole

On consideration of a patent application for an invention relating to the measurement of blood flow in a haemodialysis shunt used in the process of dialysis the European Patent Office (“EPO”) has applied...

Tags on this discussion: Article 53 (c) devices Enlarged Board of Appeal european case law European law European patent European Patent Convention European Patent Office European Union European Union law Intellectual property intellectual property law intellectual property rights invent invention Inventions IP IP law patent patent applications patent law patentability patentability exclusion Patents pharma pharmaceutical pharmaceutical business pharmaceutical company pharmaceutical patents pharmaceutical products pharmaceutical sector surgical method exclusion technology patent

Protect Your Position – Bristol-Myers buys Inhibitex for $2.5 billion

17 January 2012 | Laura Mole

With the Patent Cliff looming and the lack of new drugs to fill the void keeping big Pharma bosses awake at night, we are seeing new strategies emerging in an attempt to off see the gloom and doom predictions...

Tags on this discussion: acquisitions big pharma commercial commercial contracts contract corporate hepatitis C Intellectual property intellectual property rights IP IP protection IP rights IPR M&A medicine patent medicines medicines patent merger merger and acquisitions Mergers and acquisitions patent patent cliff patent law patented Patents Patents Act 1977 pharma pharma products pharmaceutical pharmaceutical business pharmaceutical company pharmaceutical industry pharmaceutical market pharmaceutical patents pharmaceutical products pharmaceutical sector Upload-Pharma

“The Patent Cliff – Lipitor goes over the Edge”

12 December 2011 | Laura Mole

As the largest ever number of patents protecting the pharmaceutical industry’s most profitable “blockbuster” drugs are set to expire, for India and China it’s going to be a very merry Christmas...

Tags on this discussion: brand brand protection branding brands Commercial contract contract generic generic drugs generics infringement Intellectual property intellectual property rights intellectual property rights infringement IP IP infringement IPR infringement medicine patent medicines patent patent patent cliff patent infringement patent law patented Patents Patents Act 1977 pharmaceutical patents unauthorised unlawful

Trainee Solicitor

Laura Mole

Latest news and views from Laura Mole

European Patent Office apply Enlarged Board of Appeal Ruling on the Surgical Method Exclusion from Patentability

Protect Your Position – Bristol-Myers buys Inhibitex for $2.5 billion

“The Patent Cliff – Lipitor goes over the Edge”

About us

Contact us

View latest Upload